Pure Global AI
NCT06247865Not yet recruiting

BIO-CHECKPOINT 0 Biomarkers to Identify Oncology Patients on ICPI at Greater Risk of irAE

Characterising Biomarkers and Clinical Algorithms to Identify Oncology Patients on Immune Checkpoint Inhibitors (ICPI) That Are at Greater Risk of Developing Immune-related Adverse Events (irAE)
Portsmouth Hospitals NHS TrustClinicalTrials.gov
Verified
Study focus
Disease/Condition
Neoplasms
Study type
Observational
Sponsor & location
Primary sponsor
Portsmouth Hospitals NHS Trust
Location
Portsmouth, United Kingdom
Timeline & enrollment
Phase
N/A
Start date
Mar 01, 2024
End date
May 01, 2025
Enrollment
120 participants
Primary outcome

Prediction of patient risk of irAE.

Summary

The study will collect leftover clinic blood samples on new oncology ICPI patients and test
 them for routine blood tests and malondialdehyde. Malondialdehyde can assess the body's
 oxidative stress level, a condition where your body lacks antioxidants. The NHS does not
 offer a malondialdehyde test presently, the study would produce a new NHS blood test. Once
 testing is completed the samples will be destroyed. Blood test results will be correlated to
 the patient's outcome i.e., did they have an irAE and assess if there are any differences in
 the results. From this information, the investigators hope to understand which blood tests
 help to highlight if a patient is at risk of developing irAE before it occurs.

ICD-10 classifications
NeoplasmsIn situ neoplasmsPersonal history of other neoplasmsBenign neoplasmsMalignant neoplasms
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06247865
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06247865 through Pure Global AI's free database. This phase not specified trial is sponsored by Portsmouth Hospitals NHS Trust and is currently Not yet recruiting. The study focuses on Neoplasms. Target enrollment is 120 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.